Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nucleic Acid–Based Therapies for Atherosclerosis

1 Feb 2020

Abstract excerpt

PURPOSE OF REVIEW: Atherosclerosis is characterized by accumulation of lipids and chronic inflammation in medium size to large arteries. Recently, RNA-based antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are being developed, along with small molecule-based drugs and monoclonal antibodies, for the treatment of risk factors associated with atherosclerosis.. The purpose of this review is to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lipid metabolism and disorders
Share to Lipoproteins and Cardiovascular Health
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32034521
DOI: 10.1007/s11883-020-0826-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nucleic Acid–Based Therapies for AtherosclerosisPMID 32034521Read ↗

Advances in nucleic acid-targeted therapies for cardiovascular disease preventionSemantic proximity Read ↗

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?Semantic proximity Read ↗

Updates in Small Interfering RNA for the Treatment of DyslipidemiasSemantic proximity Read ↗

Gene-based therapy in lipid management: the winding road from promise to practiceSemantic proximity Read ↗

Treatment of Lp(a): Is It the Future or Are We Ready Today?Semantic proximity Read ↗

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseSemantic proximity Read ↗

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factorSemantic proximity Read ↗

Lipoprotein(a)Semantic proximity Read ↗

Therapeutic implications of small interfering <scp>RNA</scp> in cardiovascular diseasesSemantic proximity Read ↗

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansSemantic proximity Read ↗

Advances in biological therapies for dyslipidemias and atherosclerosisSemantic proximity Read ↗

A new dawn for managing dyslipidemias: The era of rna-based therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.